🔎 Trials Near Me

Home › Lymphoma › Florida

Lymphoma clinical trials in Florida

25 studies for Lymphoma are looking for participants at sites in Florida.

Cities in Florida

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

  • Moffitt Cancer Center, Tampa
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07015242

Precise Oncology Interventions in Nutrition and Training (OnPoint)

  • University of Miami, Miami
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT06534918

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

  • University of Miami, Coral Gables
  • Florida Cancer Specialists, Sarasota
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07221500

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  • Research Site, Miami
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 14, 2026 · NCT06137144

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

  • Johns Hopkins All Children's Hospital, St. Petersburg
RecruitingPhase 1/2
12 Months – 21 Years · All sexes · Updated Sep 11, 2026 · NCT04870944

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  • AdventHealth Cancer Institute, Orlando
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 8, 2026 · NCT06624085

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Mayo Clinic, Jacksonville
  • Moffitt Cancer Center, Tampa
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 3, 2026 · NCT04588922

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

  • University of Miami, Coral Gables
  • Moffitt Cancer Center, Tampa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06084936

A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma

  • Moffit Cancer Center, Tampa
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT07192471

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

  • Mayo Clinic, Clinical Trials Referral Office, Jacksonville
RecruitingPhase 1/2
Ages 13 to 90 · All sexes · Updated Aug 6, 2026 · NCT06533579

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Mayo Clinic Florida, Jacksonville
  • AdventHealth, Orlando
  • Moffitt Cancer Center, Tampa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Baptist Health Miami Cancer Institute, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

  • University of Miami, Miami
  • Florida Cancer Specialists, Sarasota
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022

CD4CAR for CD4+ Leukemia and Lymphoma

  • University of Miami Sylvester Comprehensive Cancer Center, Miami
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Jun 24, 2026 · NCT03829540

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

  • Dren Investigational Site, Tampa
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT05475925

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

  • University of Miami, Miami
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT05663502

xDRIVE for Florida-based Cancer Patients

  • First Ascent Biomedical, Miami
Recruiting
All ages · All sexes · Updated May 19, 2026 · NCT07167381

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Golisano Children's Hospital of Southwest Florida, Fort Myers
  • Nemours Children's Clinic-Jacksonville, Jacksonville
  • Nemours Children's Hospital, Orlando
  • and 2 more
RecruitingObservational study
All ages · All sexes · Updated May 18, 2026 · NCT01790152

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

  • Mayo Clinic, Jacksonville
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 16, 2026 · NCT03328078

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • ASCLEPES Research Centers, Weeki Wachee
RecruitingPhase 1/2
Ages 12 to 95 · All sexes · Updated Apr 15, 2026 · NCT04329728

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

  • University of Miami Sylvester Cancer Center, Miami
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT05800366

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

  • Sylvester Comprehensive Cancer Center, Miami
Recruiting
Ages 18 and older · All sexes · Updated Feb 20, 2026 · NCT05745285

A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

  • Hematology-Oncology Associates of the Treasure Coast, Port Saint Lucie
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 4, 2026 · NCT05892718

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • Miami Cancer Institute, Miami
RecruitingObservational studyHealthy volunteers welcome
Ages 40 and older · All sexes · Updated Jan 20, 2026 · NCT05366881

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.